依特普生治疗杜氏肌营养不良:外显子跳跃与抗肌萎缩蛋白生成
研究202为随机对照研究201的观察性开放标签扩展,评估依特普生30或50 mg/kg每周静脉给药对DMD患者的外显子51跳跃及新抗肌萎缩蛋白生成的作用,通过4种方法证实治疗患者出现外显子跳跃及抗肌萎缩蛋白表达增加。
要点
- 所有接受治疗患者均显示预期的外显子51跳跃序列。
- 治疗患者抗肌萎缩蛋白含量较未治疗对照增加11.6倍(p=0.007)。
- 抗肌萎缩蛋白阳性纤维比例较对照增加7.4倍(p<0.001),复核为15.5倍。
核心结论
- 4种基于不同评估机制的检测方法共同提供证据,表明依特普生可穿透肌细胞、诱导外显子跳跃并促进新抗肌萎缩蛋白表达。
研究设计与样本
- 研究202为观察性开放标签扩展研究,纳入随机对照研究201中经确认DMD基因突变适合外显子51跳跃矫正的DMD患者。
- 患者接受依特普生30或50 mg/kg每周一次静脉给药。
- 在联合研究第180周采集上肢肌肉活检样本,盲法评估抗肌萎缩蛋白相关含量。
主要发现
- 逆转录PCR及新形成剪接接头测序确认100%接受治疗患者显示预期的外显子51跳跃序列。
- 治疗患者 vs 未治疗对照:Western blot显示抗肌萎缩蛋白含量增加11.6倍(p=0.007)。
- 治疗患者 vs 未治疗对照:抗肌萎缩蛋白阳性纤维比例增加7.4倍(p<0.001),复核样本显示增加15.5倍(p<0.001)。
- 治疗患者 vs 未治疗对照:抗肌萎缩蛋白免疫荧光强度增加2.4倍(p<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe the quantification of novel dystrophin production in patients with Duchenne muscular dystrophy (DMD) after long-term treatment with eteplirsen. METHODS: Clinical study 202 was an observational, open-label extension of the randomized, controlled study 201 assessing the safety and efficacy of eteplirsen in patients with DMD with a confirmed mutation in the DMD gene amenable to correction by skipping of exon 51. Patients received once-weekly IV doses of eteplirsen 30 or 50 mg/kg. Upper extremity muscle biopsy samples were collected at combined study week 180, blinded, and assessed for dystrophin-related content by Western blot, Bioquant software measurement of dystrophin-associated immunofluorescence intensity, and percent dystrophin-positive fibers (PDPF). Results were contrasted with matched untreated biopsies from patients with DMD. Reverse transcription PCR followed by Sanger sequencing of newly formed slice junctions was used to confirm the mechanism of action of eteplirsen. RESULTS: Reverse transcription PCR analysis and sequencing of the newly formed splice junction confirmed that 100% of treated patients displayed the expected skipped exon 51 sequence. In treated patients vs untreated controls, Western blot analysis of dystrophin content demonstrated an 11.6-fold increase (p = 0.007), and PDPF analysis demonstrated a 7.4-fold increase (p < 0.001). The PDPF findings were confirmed in a re-examination of the sample (15.5-fold increase, p < 0.001). Dystrophin immunofluorescence intensity was 2.4-fold greater in treated patients than in untreated controls (p < 0.001). CONCLUSION: Taken together, the 4 assays, each based on unique evaluation mechanisms, provided evidence of eteplirsen muscle cell penetration, exon skipping, and induction of novel dystrophin expression. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence of the muscle cell penetration, exon skipping, and induction of novel dystrophin expression by eteplirsen, as confirmed by 4 assays.
引用
- Charleston JS, Schnell FJ, Dworzak J, et al. Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production. Neurology. 2018. PMID: 29752304. doi:10.1212/WNL.0000000000005680
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。